Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat

NCT00156897 is registered in ClinicalTrials.gov with Alizyme as lead sponsor.

NCT NCT00156897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00156897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat
Lead sponsor
Alizyme
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2004
Completion date
October 31, 2005
Enrollment
600
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

non-insulin-dependent diabetes mellitus, obesity